Key facts
- Octozi’s last known valuation is $2.5M (Jun 2024).
- It has raised $150K; the latest was Seed Round in Jun 2025.
- Notable investors include Entrepreneurs Roundtable Accelerator, PharmStars, Debiopharm Innovation Fund.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for Octozi
- ·The full record, as it builds
Funding rounds
No funding rounds for Octozi are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Octozi
Developer of language models specifically designed to automate workflows in the clinical development process for the pharmaceutical and biotechnology industries. The company's AI agents use natural language processing to clean data and generate documents in real time, adhering to good practices and regulatory guidance, enabling clients to improve data quality, expedite regulatory submissions, and minimize errors and delays in clinical trials.
- Sector
- Healthcare
- HQ
- New York, NY, United States
- Founded
- 2023
- Employees
- 5
- Website
- octozi.com/
- Ownership
- Privately Held (backing)
Octozi doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Octozi shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Octozi in its N-PORT filings yet. We sweep new filings monthly.